TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1340835

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus Metronidazole (TG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 63
Study: 6367414

Group type: EXPERIMENTAL
Intervention: Bepridil (400 mg once a day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30312434

Group type: EXPERIMENTAL
Intervention: CTC-positive status 2 years after chemotherapy
Number of subjects: 1087

Group type: COMPARATOR
Intervention: CTC-negative status 2 years after chemotherapy
Number of subjects: 1087
Study: 30192414

Group type: EXPERIMENTAL
Intervention: EHF W1 (Aptamil Pepti 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHF W2 (Althera)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHF C1 (Similac Alimentum)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EHF C2 (Nutramigen LGG 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall expectation of better palatability
Number of subjects: 100
Study: 26895988

Group type: EXPERIMENTAL
Intervention: Gelatine tannate (250 mg, 4 times/day for children younger than 3 years; 500 mg, 4 times/day for children older than 3 years)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25311284

Group type: EXPERIMENTAL
Intervention: OLT (interactive, multimedia online training)
Number of subjects: 181

Group type: COMPARATOR
Intervention: OLT+ME (OLT plus a brief, computerized motivational enhancement intervention)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: OLT+ME+LC (OLT+ME plus a Web‐based learning community)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: OLT+ME+LC
Number of subjects: 181
Study: 23074247

Group type: EXPERIMENTAL
Intervention: Intranasal OXT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20151053

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg based on an algorithm)
Number of subjects: 1258
Study: 17702967

Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 86
Study: 16178185

Group type: EXPERIMENTAL
Intervention: ProFile
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hero 642
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stainless steel K files
Number of subjects: 80
Study: 11897771

Group type: EXPERIMENTAL
Intervention: ETRA (SB 209670) - a dual endothelin type A/endothelin type B receptor antagonist
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects (healthy age-matched)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hypertension patients
Number of subjects: 23
Study: 10204835

Group type: EXPERIMENTAL
Intervention: Fructose (30 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glucose (17.5 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aspartame (1 g)
Number of subjects: 22
Study: 7779330

Group type: EXPERIMENTAL
Intervention: TENS parameters (110 Hz, 200 microseconds)
Number of subjects: 88

Group type: COMPARATOR
Intervention: TENS parameters (50 microseconds & 4 Hz)
Number of subjects: 88

Group type: COMPARATOR
Intervention: TENS parameters (50 microseconds & 110 Hz)
Number of subjects: 88

Group type: COMPARATOR
Intervention: TENS parameters (200 microseconds & 4 Hz)
Number of subjects: 88
Study: 1981996

Group type: EXPERIMENTAL
Intervention: Oxatomide gel at 5% applied twice a day for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Follow-up without therapy for 14 days
Number of subjects: 30
Study: 465619

Group type: EXPERIMENTAL
Intervention: Propranolol (0.25 mg/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study: 31596646

Group type: EXPERIMENTAL
Intervention: DLD group
Number of subjects: 234

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: LTM × Group interaction
Number of subjects: 234
Study: 28293966

Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction
Number of subjects: 110

Group type: COMPARATOR
Intervention: Isolated ACL reconstruction
Number of subjects: 110
Study: 26895002

Group type: EXPERIMENTAL
Intervention: Active Warming (AW) - warmed IV fluid and lower body forced-air warmer
Number of subjects: 46

Group type: COMPARATOR
Intervention: No Warming (NW) - blankets only
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Active Warming (AW)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No Warming (NW)
Number of subjects: 46
Study: 24931228

Group type: EXPERIMENTAL
Intervention: Aspirin combined with mechanical measures
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) sodium and rivaroxaban sequentially combined with mechanical measures
Number of subjects: 120
Study: 22104610

Group type: EXPERIMENTAL
Intervention: 200 μg of inhaled budesonide twice per day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 19958872

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) at 90% of maximum heart rate, 5 d/wk, for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Moderate continuous training (MCT) at 70% of maximum heart rate, 5 d/wk, for 4 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both AIT and MCT
Number of subjects: 59
Study: 17257742

Group type: EXPERIMENTAL
Intervention: First screening round
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 1548
Study: 15009856

Group type: EXPERIMENTAL
Intervention: Coronary sinus pacing (PCS leads)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coronary sinus pacing (DCS leads)
Number of subjects: 24
Study: 12172328

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg / Indapamide 0.625 mg
Number of subjects: 2907

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg / Indapamide 1.25 mg
Number of subjects: 2907

Group type: EXPERIMENTAL
Intervention: Higher dosages of Perindopril and Indapamide
Number of subjects: 2907

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2907
Study: 10431027

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7795086

Group type: EXPERIMENTAL
Intervention: Oral paste and solution containing polymyxin, gentamicin, and nystatin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo paste and solution
Number of subjects: 61
Study: 2094065

Group type: EXPERIMENTAL
Intervention: Glucose-fructose-xylitol solution (GFX-B) - 10.5% solution, infused continuously for 3 days postoperatively
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sole glucose solution (PHY-3) - 10% glucose solution, infused continuously for 3 days postoperatively
Number of subjects: 24
Study: 558547

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression of the calf for 5 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 128
Study: 31872555

Group type: COMPARATOR
Intervention: Whole grain millet diets (0%, 20%, 40%, 60%, 80%, 100% inclusion)
Number of subjects: 540
Study: 31227673

Group type: EXPERIMENTAL
Intervention: Real tDCS + resistance training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS + resistance training
Number of subjects: 14
Study: 28594657

Group type: EXPERIMENTAL
Intervention: Sitting interspersed with 5 min light walking bouts every 30 min
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prolonged sitting
Number of subjects: 34
Study: 26032878

Group type: EXPERIMENTAL
Intervention: Suction/Inspiration against resistance
Number of subjects: 15
Study: 23909742

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (30 mg.kg(‐1) bolus followed by 10 mg.kg(‐1).h(‐1) continuous infusion)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline 0.9% (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (magnesium and control)
Number of subjects: 70
Study: 21896825

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 12.5 mg/kg/day for 2 days plus Artesunate (AS) 4.0 mg/kg/day for 3 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study: 19839251

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg bid
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 16102684

Group type: EXPERIMENTAL
Intervention: Group A (antecubital; n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group D (dorsum hand; n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall measurements
Number of subjects: 30
Study: 10624255

Group type: EXPERIMENTAL
Intervention: Homoeopathy treatment, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8942578

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at a rate of 4 micrograms.kg‐1.min‐1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no dobutamine infusion)
Number of subjects: 16
Study: 1958393

Group type: EXPERIMENTAL
Intervention: Alizapride (16 mg/kg) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alizapride (16 mg/kg) + Dexamethasone (40 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metoclopramide (4 mg/kg) + Dexamethasone (40 mg)
Number of subjects: 21
Study: 6807152

Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 13
Study: 30799142

Group type: EXPERIMENTAL
Intervention: Novartis Access (intervention)
Number of subjects: 639
Study: 30104294

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Insulin degludec 100 units/mL (IDeg‐100)
Number of subjects: 929
Study: 27159857

Group type: EXPERIMENTAL
Intervention: Superpulsed low level laser therapy (SLLLT) at T0, 24 hours, and 48 hours with a GaAs laser diode
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control site (no SLLLT treatment)
Number of subjects: 25
Study: 24121243

Group type: EXPERIMENTAL
Intervention: Active video games (AVG) using a Wii Nintendo console with the game Wii Fit Plus for 40 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 22894891

Group type: EXPERIMENTAL
Intervention: Yoga classes (hatha yoga) held twice a week for 10 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no yoga classes)
Number of subjects: 27
Study: 19639858

Group type: EXPERIMENTAL
Intervention: Tailored e-mail messages based on participants' identified needs
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison group (no tailored e-mail messages)
Number of subjects: 73
Study: 17617554

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 200
Study: 15035240

Group type: EXPERIMENTAL
Intervention: Parental positioning and distraction
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (comparison)
Number of subjects: 43
Study: 12685875

Group type: EXPERIMENTAL
Intervention: Insulin monotherapy (n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insulin plus glibenclamide (n = 6)
Number of subjects: 14
Study: 9655776

Group type: EXPERIMENTAL
Intervention: Repeat cold-water immersion (2 hours in 20 degrees C water, three times a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single cold-water immersion (Control)
Number of subjects: 8
Study: 7661746

Group type: COMPARATOR
Intervention: Body mass index < 22
Number of subjects: 17764

Group type: EXPERIMENTAL
Intervention: Body mass index 22 to < 25
Number of subjects: 17764

Group type: EXPERIMENTAL
Intervention: Body mass index 25 to < 27.8
Number of subjects: 17764

Group type: EXPERIMENTAL
Intervention: Body mass index 27.8 or more
Number of subjects: 17764

Group type: EXPERIMENTAL
Intervention: Increase in body mass index by 2 units
Number of subjects: 17764

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 17764
Study: 30183453

Group type: EXPERIMENTAL
Intervention: Neurac vibration during side-lying bridge exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Side-lying bridge exercise without Neurac vibration
Number of subjects: 30
Study: 29953626

Group type: EXPERIMENTAL
Intervention: Community HUGS (CHUGS) intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 74
Study: 27306315

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBTuhr)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 196
Study: 26268565

Group type: EXPERIMENTAL
Intervention: Omegaven (omega-3 fatty acids)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 22377324

Group type: EXPERIMENTAL
Intervention: 1.5g HA‐CMC
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 27
Study: 21486265

Group type: EXPERIMENTAL
Intervention: Positive parenting behaviors toward 14-month-old children
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Supportive parenting, higher family resources, lower family conflict
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Supportive parenting, support for language and learning in the home environment, higher family resources
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 1240
Study: 19646783

Group type: EXPERIMENTAL
Intervention: Rotecno gowns
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gore gowns
Number of subjects: 56
Study: 17766507

Group type: EXPERIMENTAL
Intervention: Perceived milk intolerance
Number of subjects: 291

Group type: COMPARATOR
Intervention: Lactose maldigestion
Number of subjects: 291
Study: 15153167

Group type: EXPERIMENTAL
Intervention: Azathioprine continued treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Azathioprine withdrawal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Azathioprine continued treatment (dose >1.60 mg/kg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Azathioprine withdrawal (dose >1.60 mg/kg/day)
Number of subjects: 29
Study: 11485124

Group type: EXPERIMENTAL
Intervention: Sulfasalazine 500 mg tablets twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9589379

Group type: EXPERIMENTAL
Intervention: DM-CRF (patients with diabetes mellitus and chronic renal failure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: non-DM-CRF (patients with renal failure due to other causes)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus (DM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher serum creatinine levels
Number of subjects: 40
Study: 7602728

Group type: EXPERIMENTAL
Intervention: Auscultation (progression of loudest sound locations from left to right abdomen)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vacuum effect (change from 40 mL of aspirated air to ≤ 10 mL after 60 mL of air instillation)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: pH change (from ≤ 4.0 to ≥ 6.0)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Color change (to yellow)
Number of subjects: 106
Study: 3245698

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB)
Number of subjects: 0
Study: 29191136

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 26714972

Group type: EXPERIMENTAL
Intervention: Potassium levels <3.5 mEq/L
Number of subjects: 6515

Group type: EXPERIMENTAL
Intervention: Potassium levels ⩾5 mEq/L
Number of subjects: 6515

Group type: COMPARATOR
Intervention: Potassium levels 3.5 to <4 mEq/L
Number of subjects: 6515

Group type: EXPERIMENTAL
Intervention: Potassium levels ⩾4.5 mEq/L
Number of subjects: 6515
Study: 26623654

Group type: EXPERIMENTAL
Intervention: Group-based structured education workshop focused on sitting reduction, self-monitoring tool, and follow-up motivational phone call
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 187
Study: 23229850

Group type: EXPERIMENTAL
Intervention: Cholestyramine ointment (15%)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 21287417

Group type: EXPERIMENTAL
Intervention: Nutritional counseling program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 53
Study: 18952497

Group type: EXPERIMENTAL
Intervention: Pramipexole (flexibly titrated from 0.25 to 0.75mg, 2‐3h before bedtime for 12 weeks)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 16645371

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled Prostacyclin (iPGI2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous vasodilators (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled drugs (iNO and iPGI2)
Number of subjects: 58
Study: 12540121

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nd:YAP laser irradiation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acid-etch treatment
Number of subjects: 67
Study: 10971787

Group type: EXPERIMENTAL
Intervention: French-press coffee
Number of subjects: 46
Study: 8781869

Group type: COMPARATOR
Intervention: Caffeine 0 mg.kg‐1 body mass
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg.kg‐1 body mass
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg.kg‐1 body mass
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 7
Study: 1727841

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,000 mg/day, 1,250 mg/day, 1,500 mg/day, or 2,000 mg/day for 8 weeks
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,500 mg and 2,000 mg for older subjects
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin)
Number of subjects: 158
Study: 6086834

Group type: EXPERIMENTAL
Intervention: Comprehensive community treatment including a 24-hour crisis service
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard psychiatric hospital care and aftercare
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comprehensive community treatment
Number of subjects: 120
Study: 31241003

Group type: EXPERIMENTAL
Intervention: VA (virus agency) messages
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: PF (positive framing) messages
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: VA*PF (virus agency and positive framing)
Number of subjects: 216

Group type: COMPARATOR
Intervention: HA (human agency) and NF (negative framing) messages
Number of subjects: 216
Study: 29257795

Group type: EXPERIMENTAL
Intervention: Halftime rewarm-up (RW) with intermittent exercise for 15 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (resting on a chair during halftime)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Halftime rewarm-up (RW) with intermittent exercise
Number of subjects: 10
Study: 26584896

Group type: EXPERIMENTAL
Intervention: Pain Recognition and Treatment (PRT) protocol coupled with basic pain education
Number of subjects: 195

Group type: COMPARATOR
Intervention: Basic pain education alone
Number of subjects: 195
Study: 24571483

Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 17
Study: 22424269

Group type: EXPERIMENTAL
Intervention: Super short pulse (SSP) Er:YAG laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steel bur (SB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium short pulse (MSP) Er:YAG laser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short pulse (SP) Er:YAG laser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluorescence feedback-controlled (FFC) Er:YAG laser
Number of subjects: 60
Study: 19761871

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg b.i.d.)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU b.i.d.)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Metformin or Vitamin E
Number of subjects: 173
Study: 17043050

Group type: EXPERIMENTAL
Intervention: Internet-mediated individualized intervention (52 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 82
Study: 15505091

Group type: EXPERIMENTAL
Intervention: Additional ablation lines along the left atrial septum, roof, and/or anterior wall where there were fractionated electrograms (group 3; 30 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No further ablation (group 2; 30 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Left atrial flutter
Number of subjects: 100
Study: 11273580

Group type: EXPERIMENTAL
Intervention: Valid colour cues in a high-load condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colour cues in a low-load condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of target colour
Number of subjects: 0
Study: 9805215

Group type: EXPERIMENTAL
Intervention: Low-fat ice cream (3% fat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard ice cream (10% fat)
Number of subjects: 16
Study: 7999483

Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events (regardless of smoking status)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 0
Study: 3056240

Group type: EXPERIMENTAL
Intervention: Clindamycin (total dose, 2.4 g) plus Amikacin (total dose, 1 g)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ticarcillin plus Clavulanic acid (total dose, 20.8 g)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Clindamycin plus Amikacin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ticarcillin plus Clavulanic acid
Number of subjects: 113
Study: 31104113

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40